Here's How Nektar Therapeutics Performed in Q4
It's been a wild ride for shareholders of Nektar Therapeutics (NASDAQ: NKTR) so far in 2020. The stock got off to a great start, soaring more than 20%. But Nektar gave up all of those gains and then some after two U.S. Food and Drug Administration (FDA) advisory committees voted against recommending approval for experimental pain drug oxycodegol.
Nektar announced its fourth-quarter results after the market closed on Thursday. Investors seemed to have liked what they heard, with shares up around 6% in after-hours trading. Here are the highlights from Nektar's Q4 update.
Image Source: Getty Images.
Source Fool.com
